Advancements Improved Skin Cancer Care Options
Dermatologists discussed new tools to manage complex cases of cutaneous squamous cell carcinoma.
Updated on Oct. 11, 2026 in Cancer
Live Poll
Should federal policy prevent Medicare reimbursement cuts to maintain patient access to dermatological care?
Experts highlighted the latest treatment landscape for cutaneous squamous cell carcinoma at the Fall Clinical Dermatology Conference. While most cases remain highly treatable, new strategies are emerging for managing the 5% of instances that prove difficult to address.
Why it matters
As dermatologists serve as the primary detectors for skin cancer, ongoing access to timely diagnostic tools is critical for patient outcomes. Proposed Medicare cuts threaten to disrupt this care, potentially creating delays that could complicate treatment for older adults.
Experts noted that 95% of cutaneous squamous cell carcinoma cases are treatable, while 5% remain difficult to manage. Currently, three immune checkpoint inhibitors—pembrolizumab, cemiplimab, and cosibelimab—are approved for locally advanced and metastatic disease.
The players
Trotter
A clinical expert who specializes in dermatology and presented on cutaneous squamous cell carcinoma treatments.
Todd E. Schlesinger
A dermatologist who co-presented data on the management of skin cancer cases.
The details
Immune checkpoint inhibitors work by enabling the body's immune system to recognize and attack cancerous cells. Beyond these therapies, researchers are exploring augmented intelligence to assist clinicians in more accurate diagnosis. Additionally, gene expression profiling is being studied as a future method to help guide therapeutic decision-making for complex cases.
Timeline
October 10, 2026: The Fall Clinical Dermatology Conference was held in Las Vegas.
Health Landscape
This development aligns with the evolving diagnostic standards presented at the Fall Clinical Dermatology Conference. The focus on integrating augmented intelligence marks a shift toward more precise, technology-assisted detection methods in dermatology.
If you are concerned about persistent skin changes, consult your primary care physician or a dermatologist to ensure early detection. Because proposed Medicare changes may impact future access to care, it is worth discussing the timing of screenings with your doctor.
The takeaway
While most skin cancer cases are manageable, staying vigilant through regular skin exams is essential. Ask your dermatologist about the role of advanced diagnostics during your next checkup to ensure you have the most up-to-date information on your skin health.
Further reading
Learn more about the latest developments in skin health in our Cancer section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should federal policy prevent Medicare reimbursement cuts to maintain patient access to dermatological care?
